Skip to main content
. 2024 Nov 20;16(22):3885. doi: 10.3390/cancers16223885

Table 1.

Ongoing clinical trials of KRAS G12C small molecule inhibitor monotherapies.

Compound Mechanism of Action Clinical Trial Indication Phase of Study
Sotorasib
(AMG510) 		KRAS G12C OFF inhibitor
  • -

    Compared to docetaxel in previously treated locally advanced or unresectable or metastatic NSCLC (NCT04303780)

  • -

    Frontline in advanced NSCLC (NCT06582771)

  • -

    Frontline in stage IV NSCLC (NCT04933695)

  • -

    Frontline in stage IIA-IIIB(NCT05118854)

  • -

    In previously treated locally advanced or metastatic NSCLC (NCT05631249)

  • -

    Stage III unresectable NSCLC ineligible for chemo-radiation therapy (NCT05398094)

  • -

    In metastatic or recurrent NSCLC (NCT04625647)

  • -

    Compared to durvalumab in locally advanced NSCLC with MRD (NCT06333678)

  • -

    Stage III/IV not amenable for curative treatment (NCT05311709)

 3

2
2
2
2

2

2
2

2
Adagrasib
(MRTX849) 		KRAS G12C OFF inhibitor
  • -

    Compared to docetaxel in advanced NSCLC (NCT04685135)

  • -

    First line with or without pembrolizumab (NCT04613596)

  • -

    In patients who are elderly or have poor performance status (NCT05673187)

  • -

    In advanced solid tumors (NCT03785249)

 3

2

2

1/2
Garsorasib
(D-1553) 		KRAS G12C OFF inhibitor
  • -

    Compared to docetaxel in locally advanced NSCLC in second line (NCT06300177)

  • -

    In advanced or metastatic NSCLC (NCT05383898)

 3

1/2
Divarasib
(GDC-6036) 		KRAS G12C OFF inhibitor 3
1
Opnurasib
(JDQ-443) 		KRAS G12C OFF inhibitor
  • -

    Second line after platinum-based chemotherapy and ICI as monotherapy compared to docetaxel (NCT05132075)

  • -

    In advanced solid tumors (NCT05358249)

 3

1/2
JDQ443 KRAS G12C OFF inhibitor
  • -

    As monotherapy compared to docetaxel in stage IIIB/IIIC or metastatic disease (NCT05132075)

 3
Glecirasib
(JAB-21822) 		KRAS G12C OFF inhibitor
  • -

    First line for locally advanced or metastatic NSCLC with PDL 1 < 1% or PD-L1 > 1% and STK11 co-mutation (NCT05445843)

  • -

    In locally advanced or metastatic NSCLC (NCT05276726)

 2

1/2
HBI-2438 KRAS G12C OFF 1
Olomorasib
(LY3537982)		 KRAS G12C OFF
  • -

    In locally advanced unresectable or metastatic NSCLC (NCT04956640)

 1/2
FMC-376 KRAS G12C ON and OFF inhibitor
  • -

    In locally advanced unresectable or metastatic solid tumors (NCT06244771)

 1/2
RMC-6291 Tri-complex (glue-based) mechanism of KRAS G12C targeting 1